Skip to main content

Tipp

Weitere Kapitel dieses Buchs durch Wischen aufrufen

2017 | OriginalPaper | Buchkapitel

4. Kollagenosen

verfasst von : Rudolf Puchner, Judith Sautner

Erschienen in: Rheumatologie aus der Praxis

Verlag: Springer Berlin Heidelberg

Zusammenfassung

Zu den Kollagenosen gehören: der systemische Lupus erythematodes (SLE), die Mischkollagenose (Mixed Connective Tissue Disease – MCTD, Sharp-Syndrom), die systemische Sklerose, das Sjögren-Syndrom und die systemischen Myositiden. Der Beitrag umfasst die Beschreibung der wichtigsten Krankheiten unter Berücksichtigung neuer Klassifikationskriterien und neuer Erkenntnisse in der Behandlung. Mehrere Fallbeispiele tragen zum Verständnis diagnostischer Schritte und komplexer Therapieentscheidungen bei.
Literatur
[1]
Zurück zum Zitat Abraham DJ, Krieg T, Distler J, Distler O (2009) Overview of pathogenesis of systemic sclerosis. Rheumatology 48 [Suppl 3]:iii 3–7 (Review) Abraham DJ, Krieg T, Distler J, Distler O (2009) Overview of pathogenesis of systemic sclerosis. Rheumatology 48 [Suppl 3]:iii 3–7 (Review)
[2]
Zurück zum Zitat Amato AA, Griggs RC (2003) Treatment of idiopathic inflammatory myopathies. Curr Opin Neurol 16:569–575 CrossRefPubMed Amato AA, Griggs RC (2003) Treatment of idiopathic inflammatory myopathies. Curr Opin Neurol 16:569–575 CrossRefPubMed
[3]
Zurück zum Zitat Andreoli L, Bertsias GK, Agmon-Levin N et al. (2016) EULAR recommendations for women’s health and the management of family planning, assisted reproduction, pregnancy and menopause in patients with systemic lupus erythematosus and/or antiphospholipid syndrome. Ann Rheum Dis Jul 25. Epub ahead of print. doi: 10.​1136/​annrheumdis-2016-209770 Andreoli L, Bertsias GK, Agmon-Levin N et al. (2016) EULAR recommendations for women’s health and the management of family planning, assisted reproduction, pregnancy and menopause in patients with systemic lupus erythematosus and/or antiphospholipid syndrome. Ann Rheum Dis Jul 25. Epub ahead of print. doi: 10.​1136/​annrheumdis-2016-209770
[4]
[5]
Zurück zum Zitat Aringer M, Steiner G, Smolen JS (2005) Does mixed connective tissue disease exist? Yes. Rheum Dis Clin North Am 31:411–442 CrossRefPubMed Aringer M, Steiner G, Smolen JS (2005) Does mixed connective tissue disease exist? Yes. Rheum Dis Clin North Am 31:411–442 CrossRefPubMed
[6]
Zurück zum Zitat Bertsias GK, Ionnidis JPA, Boletis J et al. (2008) EULAR recommendations for the management of systemic lupus erythematosus. Report of a task force of the EULAR standing committee for international clinical studies including therapeutics (ESCISIT). Ann Rheum Dis 67:195–205 CrossRefPubMed Bertsias GK, Ionnidis JPA, Boletis J et al. (2008) EULAR recommendations for the management of systemic lupus erythematosus. Report of a task force of the EULAR standing committee for international clinical studies including therapeutics (ESCISIT). Ann Rheum Dis 67:195–205 CrossRefPubMed
[7]
Zurück zum Zitat Bertsias GK, Ioannidis JP, Aringer M et al. (2010) EULAR recommendations for the management of systemic lupus erythematosis with neuropsychiatric manifestations: report of a task force of the EULAR standing committee for clinical affairs. Ann Rheum Dis 69(12):2074–2082 CrossRefPubMed Bertsias GK, Ioannidis JP, Aringer M et al. (2010) EULAR recommendations for the management of systemic lupus erythematosis with neuropsychiatric manifestations: report of a task force of the EULAR standing committee for clinical affairs. Ann Rheum Dis 69(12):2074–2082 CrossRefPubMed
[8]
Zurück zum Zitat Blank N, Max R, Lorenz HM (2006) The role of DMARDs in systemic sclerosis therapy. Rheumatology 45 [Suppl 3]:iii 2–4 Blank N, Max R, Lorenz HM (2006) The role of DMARDs in systemic sclerosis therapy. Rheumatology 45 [Suppl 3]:iii 2–4
[9]
Zurück zum Zitat Bohan A, Peter JB (1975) Polymyositis and dermatomyositis (first of two parts). N Engl J Med 292:344–347 CrossRefPubMed Bohan A, Peter JB (1975) Polymyositis and dermatomyositis (first of two parts). N Engl J Med 292:344–347 CrossRefPubMed
[10]
Zurück zum Zitat Bohan A, Peter JB (1975) Polymyositis and dermatomyositis (second of two parts). N Engl J Med 292:403–407 CrossRefPubMed Bohan A, Peter JB (1975) Polymyositis and dermatomyositis (second of two parts). N Engl J Med 292:403–407 CrossRefPubMed
[11]
Zurück zum Zitat Brito-Zeron P, Theander E, Baldini C et al. (2016) Early diagnosis of primary Sjögren’s syndrome: EULAR-SS task force clinical recommendations. Expert Rev Clin Immunol 12(2): 137–156 CrossRefPubMed Brito-Zeron P, Theander E, Baldini C et al. (2016) Early diagnosis of primary Sjögren’s syndrome: EULAR-SS task force clinical recommendations. Expert Rev Clin Immunol 12(2): 137–156 CrossRefPubMed
[12]
Zurück zum Zitat Cervera R, Khamashta MA, Font J et al. (2003) Morbidity and mortality in systemic lupus erythematosus during a 10-year period: a comparison of early and late manifestations in a cohort of 1,000 patients. Medicine (Baltimore) 82:299–308 CrossRef Cervera R, Khamashta MA, Font J et al. (2003) Morbidity and mortality in systemic lupus erythematosus during a 10-year period: a comparison of early and late manifestations in a cohort of 1,000 patients. Medicine (Baltimore) 82:299–308 CrossRef
[13]
Zurück zum Zitat Cipriani P, Di Benedetto P, Ruscitti P et al. (2015) Macitentan inhibits the transforming growth factor-β profibrotic action, blocking the signaling mediated by the ETR/TβRI complex in systemic sclerosis dermal fibroblasts. Arthritis Res Ther 17:247 CrossRefPubMedPubMedCentral Cipriani P, Di Benedetto P, Ruscitti P et al. (2015) Macitentan inhibits the transforming growth factor-β profibrotic action, blocking the signaling mediated by the ETR/TβRI complex in systemic sclerosis dermal fibroblasts. Arthritis Res Ther 17:247 CrossRefPubMedPubMedCentral
[14]
Zurück zum Zitat Cummins MJ, Papas A, Kammer GM, Fox PC (2003) Treatment of primary Sjogren’s syndrome with low-dose human interferon alfa administered by the oromucosal route: Combined phase III results. Arthritis Rheum 49:585–593 CrossRefPubMed Cummins MJ, Papas A, Kammer GM, Fox PC (2003) Treatment of primary Sjogren’s syndrome with low-dose human interferon alfa administered by the oromucosal route: Combined phase III results. Arthritis Rheum 49:585–593 CrossRefPubMed
[15]
[16]
Zurück zum Zitat Dörner T (2008) Sjögren-Syndrom. In: Zeidler H, Zacher J, Hiepe F (Hrsg) Interdisziplinäre klinische Rheumatologie, 2. Aufl. Springer, Berlin Heidelberg New York, S 817–824 CrossRef Dörner T (2008) Sjögren-Syndrom. In: Zeidler H, Zacher J, Hiepe F (Hrsg) Interdisziplinäre klinische Rheumatologie, 2. Aufl. Springer, Berlin Heidelberg New York, S 817–824 CrossRef
[17]
Zurück zum Zitat Dörner T, Gromnica-Ihle E (2006) Sjögren-Syndrom, Kapitel 4.1. In: Meyer J et al. (Hrsg) Rationelle Diagnostik und Therapie in der Inneren Medizin. Elsevier/Urban & Fischer, München Dörner T, Gromnica-Ihle E (2006) Sjögren-Syndrom, Kapitel 4.1. In: Meyer J et al. (Hrsg) Rationelle Diagnostik und Therapie in der Inneren Medizin. Elsevier/Urban & Fischer, München
[18]
Zurück zum Zitat Feist E, Dörner T, Hansen A (2007) Indikation und Option neuer immunmodulatorischer Therapien beim Sjögren-Syndrom. Z Rheumatol 66:679–685 CrossRefPubMed Feist E, Dörner T, Hansen A (2007) Indikation und Option neuer immunmodulatorischer Therapien beim Sjögren-Syndrom. Z Rheumatol 66:679–685 CrossRefPubMed
[19]
Zurück zum Zitat Fischer-Betz R, Schneider M (2008) Lupus erythematodes-evidenzbasierte Empfehlungen zu Überwachung und Therapie. Z Rheumatol 67:491–499 CrossRef Fischer-Betz R, Schneider M (2008) Lupus erythematodes-evidenzbasierte Empfehlungen zu Überwachung und Therapie. Z Rheumatol 67:491–499 CrossRef
[21]
Zurück zum Zitat Fries JF, Hochberg MC, Medsger TA et al. and ACR Diagnostic and Therapeutic Criteria Committee (1994) Criteria for rheumatic disease. Different types and different functions. Arthritis Rheum 37:454–462 CrossRefPubMed Fries JF, Hochberg MC, Medsger TA et al. and ACR Diagnostic and Therapeutic Criteria Committee (1994) Criteria for rheumatic disease. Different types and different functions. Arthritis Rheum 37:454–462 CrossRefPubMed
[22]
Zurück zum Zitat Fries R, Shariat K, Wilmowsky H von, Bohm M (2005) Sildenafil in the treatment of Raynaud’s phenomenon resistant to vasodilatory therapy. Circulation 112:2980–2985 PubMed Fries R, Shariat K, Wilmowsky H von, Bohm M (2005) Sildenafil in the treatment of Raynaud’s phenomenon resistant to vasodilatory therapy. Circulation 112:2980–2985 PubMed
[23]
Zurück zum Zitat Fritzler MJ, Kinsella TD, Garbutt E (1980) The CREST syndrome: A distinct serologic entity with anticentromere antibodies. Am J Med 69:520–526 CrossRefPubMed Fritzler MJ, Kinsella TD, Garbutt E (1980) The CREST syndrome: A distinct serologic entity with anticentromere antibodies. Am J Med 69:520–526 CrossRefPubMed
[24]
Zurück zum Zitat Genth E (2008) Systemische Sklerose. In: Zeidler H, Zacher J, Hiepe F (Hrsg) Interdisziplinäre klinische Rheumatologie, 2. Aufl. Springer, Berlin Heidelberg New York, S 801–816 CrossRef Genth E (2008) Systemische Sklerose. In: Zeidler H, Zacher J, Hiepe F (Hrsg) Interdisziplinäre klinische Rheumatologie, 2. Aufl. Springer, Berlin Heidelberg New York, S 801–816 CrossRef
[25]
Zurück zum Zitat Ginzler EM, Dooley MA, Aranow C et al. (2005) Mycophenolate mofetil or intravenous cyclophosphamide for lupus nephritis. N Engl J Med 353:2219–2228 CrossRefPubMed Ginzler EM, Dooley MA, Aranow C et al. (2005) Mycophenolate mofetil or intravenous cyclophosphamide for lupus nephritis. N Engl J Med 353:2219–2228 CrossRefPubMed
[26]
Zurück zum Zitat Gladman D, Ginzler E, Goldsmith C et al. (1996) The development and initial validation of the systemic lupus international collaborating clinics/American college of rheumatology damage index for systemic lupus erythematosus. Arthritis Rheum 39:363–369 CrossRefPubMed Gladman D, Ginzler E, Goldsmith C et al. (1996) The development and initial validation of the systemic lupus international collaborating clinics/American college of rheumatology damage index for systemic lupus erythematosus. Arthritis Rheum 39:363–369 CrossRefPubMed
[27]
Zurück zum Zitat Gromnica-Ihle E (2008) Mixed connective tissue disease (Sharp-Syndrom). In: Zeidler H, Zacher J, Hiepe F (Hrsg) Interdisziplinäre klinische Rheumatologie, 2. Aufl. Springer, Berlin Heidelberg New York, S 824–830 Gromnica-Ihle E (2008) Mixed connective tissue disease (Sharp-Syndrom). In: Zeidler H, Zacher J, Hiepe F (Hrsg) Interdisziplinäre klinische Rheumatologie, 2. Aufl. Springer, Berlin Heidelberg New York, S 824–830
[28]
Zurück zum Zitat Hochberg MC (1997) Updating the ACR revised criteria for the classification of systemic lupus erythematosus. Arthritis Rheum 40:1725 CrossRefPubMed Hochberg MC (1997) Updating the ACR revised criteria for the classification of systemic lupus erythematosus. Arthritis Rheum 40:1725 CrossRefPubMed
[29]
Zurück zum Zitat Hoeper M (2003) Pulmonale arterielle Hypertonie. In: Hoeper M (Hrsg) Endothelin-Rezeptor-Antagonismus als neues Therapieprinzip bei kardiovaskulären Erkrankungen. Uni-Med, Bremen, S 30–53 Hoeper M (2003) Pulmonale arterielle Hypertonie. In: Hoeper M (Hrsg) Endothelin-Rezeptor-Antagonismus als neues Therapieprinzip bei kardiovaskulären Erkrankungen. Uni-Med, Bremen, S 30–53
[30]
Zurück zum Zitat Hoogen van den F, Khanna D, Fransen J et al. (2013) 2013 classification criteria for systemic sclerosis: an American College of Rheumatology/European League against Rheumatism collaborative initiative. Arthritis Rheum 65(11):2737–2747 CrossRef Hoogen van den F, Khanna D, Fransen J et al. (2013) 2013 classification criteria for systemic sclerosis: an American College of Rheumatology/European League against Rheumatism collaborative initiative. Arthritis Rheum 65(11):2737–2747 CrossRef
[31]
Zurück zum Zitat Korn JH, Mayes M, Matucci Cerinic M et al. (2004) Digital ulcers in systemic sclerosis: Prevention by treatment with bosentan, an oral endothelin receptor antagonist. Arthritis Rheum 50:3985–3993 CrossRefPubMed Korn JH, Mayes M, Matucci Cerinic M et al. (2004) Digital ulcers in systemic sclerosis: Prevention by treatment with bosentan, an oral endothelin receptor antagonist. Arthritis Rheum 50:3985–3993 CrossRefPubMed
[32]
Zurück zum Zitat LeRoy EC, Black C, Fleischmajer R et al. (1988) Scleroderma (systemic sclerosis): Classification subsets and pathogenesis. J Rheumatol 15:202–205 PubMed LeRoy EC, Black C, Fleischmajer R et al. (1988) Scleroderma (systemic sclerosis): Classification subsets and pathogenesis. J Rheumatol 15:202–205 PubMed
[33]
Zurück zum Zitat Masi AT, Rodnan GP, Medsger T et al. (1980) Preliminary criteria for the classification of systemic sclerosis (scleroderma). Arthritis Rheum 23:581–590 CrossRef Masi AT, Rodnan GP, Medsger T et al. (1980) Preliminary criteria for the classification of systemic sclerosis (scleroderma). Arthritis Rheum 23:581–590 CrossRef
[34]
Zurück zum Zitat Matucci-Cerinic M, Krieg T, Guillevin L et al. (2016) Elucidating the burden of recurrent and chronic digital ulcers in systemic sclerosis: long-term results from the DUO Registry. Ann Rheum Dis 75(19):1770–1776 CrossRefPubMed Matucci-Cerinic M, Krieg T, Guillevin L et al. (2016) Elucidating the burden of recurrent and chronic digital ulcers in systemic sclerosis: long-term results from the DUO Registry. Ann Rheum Dis 75(19):1770–1776 CrossRefPubMed
[35]
Zurück zum Zitat Meijer J, Meiners P, Vissink A et al. (2010) Effective rituximab treatment in primary Sjögren’s syndrome: A randomised, double-blind, placebo controlled trial. Arthritis Rheum 62:960–980 CrossRefPubMed Meijer J, Meiners P, Vissink A et al. (2010) Effective rituximab treatment in primary Sjögren’s syndrome: A randomised, double-blind, placebo controlled trial. Arthritis Rheum 62:960–980 CrossRefPubMed
[36]
[37]
Zurück zum Zitat Miyakis S, Lockshin MD, Atsumi T et al. (2006) International consensus statement on an update of the classification criteria for definite antiphospholipid syndrome (APS). J Thromb Haemost 4(2):295–306 CrossRefPubMed Miyakis S, Lockshin MD, Atsumi T et al. (2006) International consensus statement on an update of the classification criteria for definite antiphospholipid syndrome (APS). J Thromb Haemost 4(2):295–306 CrossRefPubMed
[38]
Zurück zum Zitat Navarra SV, Guzman RM, Gallacher AE et al. (2011) Efficacy and safety of belimumab in patients with systemic lupus erythematosus: a randomised, placebo controlled, phase 3 trial. Lancet 377:721–731 CrossRefPubMed Navarra SV, Guzman RM, Gallacher AE et al. (2011) Efficacy and safety of belimumab in patients with systemic lupus erythematosus: a randomised, placebo controlled, phase 3 trial. Lancet 377:721–731 CrossRefPubMed
[39]
Zurück zum Zitat Pavlov-Dolijanovic S, Damanov NS, Vujasinovic Stupar NZ et al. (2013) The value of pattern capillary changes and antibodies to predict the development of systemic sclerosis in patients with primary Raynaud’s phenomenon. Rheumatol Int 33(12):2967–2973 CrossRefPubMed Pavlov-Dolijanovic S, Damanov NS, Vujasinovic Stupar NZ et al. (2013) The value of pattern capillary changes and antibodies to predict the development of systemic sclerosis in patients with primary Raynaud’s phenomenon. Rheumatol Int 33(12):2967–2973 CrossRefPubMed
[40]
Zurück zum Zitat Petri M, Orbai AM, Alarcon GS et al. (2012) Derivation and validation of the Sytemic Lupus International Collaborating Clinics classification criteria for systemic lupus erythematosus. Arthritis Rheum 64:2677–2686 CrossRefPubMedPubMedCentral Petri M, Orbai AM, Alarcon GS et al. (2012) Derivation and validation of the Sytemic Lupus International Collaborating Clinics classification criteria for systemic lupus erythematosus. Arthritis Rheum 64:2677–2686 CrossRefPubMedPubMedCentral
[41]
Zurück zum Zitat Richter J (2015) Idiopathische Myositiden - Dermatomyositis und Polymyositis. In: Hettenkofer HJ, Schneider M, Braun J (Hrsg) Rheumatologie, 6. Aufl. Thieme, Stuttgart, S 251–262 Richter J (2015) Idiopathische Myositiden - Dermatomyositis und Polymyositis. In: Hettenkofer HJ, Schneider M, Braun J (Hrsg) Rheumatologie, 6. Aufl. Thieme, Stuttgart, S 251–262
[42]
Zurück zum Zitat Richter J, Iking-Konert C (2007) Aktuelle Therapien der Dermatomyositis und Polymyositis. Z Rheumatol 66:686–682 CrossRefPubMed Richter J, Iking-Konert C (2007) Aktuelle Therapien der Dermatomyositis und Polymyositis. Z Rheumatol 66:686–682 CrossRefPubMed
[43]
Zurück zum Zitat Riemekasten G, Dragun D (2007) Risikoadaptierte Therapien bei der systemischen Sklerose. Z Rheumatol 66:672–678 CrossRefPubMed Riemekasten G, Dragun D (2007) Risikoadaptierte Therapien bei der systemischen Sklerose. Z Rheumatol 66:672–678 CrossRefPubMed
[44]
Zurück zum Zitat Riemekasten G, Schulze-Koops H (2005) Medikamentöse vasoaktive Therapien von Mikrozirkulationsstörungen bei rheumatischen Erkrankungen. Z Rheumatol 64:123–136 CrossRefPubMed Riemekasten G, Schulze-Koops H (2005) Medikamentöse vasoaktive Therapien von Mikrozirkulationsstörungen bei rheumatischen Erkrankungen. Z Rheumatol 64:123–136 CrossRefPubMed
[46]
Zurück zum Zitat Ryden-Aulin M, Boumpas D, Bultink I et al. (2016) Off-label use of rituximab for systemic lupus erythematosus in Europe. Lupus Sci Med 6;3(1): e000163 CrossRef Ryden-Aulin M, Boumpas D, Bultink I et al. (2016) Off-label use of rituximab for systemic lupus erythematosus in Europe. Lupus Sci Med 6;3(1): e000163 CrossRef
[47]
Zurück zum Zitat Saar P, Müller-Ladner U (2006) Die systemische Sklerose – Eine rheumatologische Herausforderung. Z Rheumatol 65:429–440 CrossRefPubMed Saar P, Müller-Ladner U (2006) Die systemische Sklerose – Eine rheumatologische Herausforderung. Z Rheumatol 65:429–440 CrossRefPubMed
[48]
Zurück zum Zitat Sharp GC (1987) Diagnostic criteria for classification of MCTD. In: Kaskawa R, Sharp GC (Hrsg) Mixed connective tissue disease and anti-nuclear antibodies. Elsevier, Amsterdam, S 23–32 Sharp GC (1987) Diagnostic criteria for classification of MCTD. In: Kaskawa R, Sharp GC (Hrsg) Mixed connective tissue disease and anti-nuclear antibodies. Elsevier, Amsterdam, S 23–32
[49]
Zurück zum Zitat Sharp GC, Irvin WS, Tan EM et al. (1972) Mixed connective tissue disease. An apparently distinct rheumatic disease syndrome associated with a specific antibody to an extractable nuclear antigen (ENA). Am J Med 52:148–159 CrossRefPubMed Sharp GC, Irvin WS, Tan EM et al. (1972) Mixed connective tissue disease. An apparently distinct rheumatic disease syndrome associated with a specific antibody to an extractable nuclear antigen (ENA). Am J Med 52:148–159 CrossRefPubMed
[50]
Zurück zum Zitat Shiboski SC, Shiboski CH, Criswell L et al. (2012) New Classification Criteria for Sjögren’s Syndrome: A data-driven expert – clinician consensus approach within the SICCA Cohort. Arthritis Care Res 64:475–487 CrossRef Shiboski SC, Shiboski CH, Criswell L et al. (2012) New Classification Criteria for Sjögren’s Syndrome: A data-driven expert – clinician consensus approach within the SICCA Cohort. Arthritis Care Res 64:475–487 CrossRef
[51]
Zurück zum Zitat Sjögren HSC (1933) Zur Kenntnis der Keratoconjunctivitis sicca (Keratitis filiformis bei Hypofunktion der Tränendrüsen). Acta Ophthalmol [Suppl II]: 1–151 Sjögren HSC (1933) Zur Kenntnis der Keratoconjunctivitis sicca (Keratitis filiformis bei Hypofunktion der Tränendrüsen). Acta Ophthalmol [Suppl II]: 1–151
[52]
Zurück zum Zitat Specker C (2016) Antiphospholipidsyndrom Z Rheumatol 75:570–574 Specker C (2016) Antiphospholipidsyndrom Z Rheumatol 75:570–574
[53]
Zurück zum Zitat Tan EM, Cohen AS, Fries JF et al. (1982) The 1982 revised criteria for the classification of systemic lupus erythematosus. Arthritis Rheum 25:1271–1277 CrossRefPubMed Tan EM, Cohen AS, Fries JF et al. (1982) The 1982 revised criteria for the classification of systemic lupus erythematosus. Arthritis Rheum 25:1271–1277 CrossRefPubMed
[54]
Zurück zum Zitat Tashkin DP, Elashoff R, Clements PJ et al., Scleroderma Lung Study Research Group (2006) Cyclophosphamide versus placebo in scleroderma lung disease. N Engl J Med 354:2655–2666 CrossRefPubMed Tashkin DP, Elashoff R, Clements PJ et al., Scleroderma Lung Study Research Group (2006) Cyclophosphamide versus placebo in scleroderma lung disease. N Engl J Med 354:2655–2666 CrossRefPubMed
[55]
Zurück zum Zitat Vitali C, Bombardieri S, Jonsson R et al. (2002) European Study Group on Classification Criteria for Sjogren’s Syndrome. Classification criteria for Sjogren’s syndrome: A revised version of the European criteria proposed by the America-European Consensus Group. Ann Rheum Dis 61:554–558 CrossRefPubMedPubMedCentral Vitali C, Bombardieri S, Jonsson R et al. (2002) European Study Group on Classification Criteria for Sjogren’s Syndrome. Classification criteria for Sjogren’s syndrome: A revised version of the European criteria proposed by the America-European Consensus Group. Ann Rheum Dis 61:554–558 CrossRefPubMedPubMedCentral
[57]
Zurück zum Zitat Zintzaras E, Voulgarelis M, Moutsopoulos HM (2005) The risk of lymphoma development in autoimmune diseases: A meta-analysis. Arch Intern Med 165:2337–2344 CrossRefPubMed Zintzaras E, Voulgarelis M, Moutsopoulos HM (2005) The risk of lymphoma development in autoimmune diseases: A meta-analysis. Arch Intern Med 165:2337–2344 CrossRefPubMed
[58]
Zurück zum Zitat Zuber M, Koch B, Gause A, Pfreundschuh M (1996) Diagnose und Klassifikationskriterien in der Rheumatologie: Kollagenosen. Dtsch Med Wschr 121:913–918 CrossRefPubMed Zuber M, Koch B, Gause A, Pfreundschuh M (1996) Diagnose und Klassifikationskriterien in der Rheumatologie: Kollagenosen. Dtsch Med Wschr 121:913–918 CrossRefPubMed
Metadaten
Titel
Kollagenosen
verfasst von
Rudolf Puchner
Judith Sautner
Copyright-Jahr
2017
Verlag
Springer Berlin Heidelberg
DOI
https://doi.org/10.1007/978-3-662-53569-1_4